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Abstract: A role for the minichromosome maintenance (MCM) proteins in cancer initiation and progression is slowly 
emerging. Functioning as a complex to ensure a single chromosomal replication per cell cycle, the six family mem-
bers have been implicated in several neoplastic disease states, including breast cancer. Our study aim to investigate 
the prognostic significance of these proteins in breast cancer. We studied the expression of MCMs in various data-
sets and the associations of the expression with clinicopathological parameters. When considered alone, high level 
MCM4 overexpression was only weakly associated with shorter survival in the combined breast cancer patient co-
hort (n = 1441, Hazard Ratio = 1.31; 95% Confidence Interval = 1.11-1.55; p = 0.001). On the other hand, when we 
studied all six components of the MCM complex, we found that overexpression of all MCMs was strongly associated 
with shorter survival in the same cohort (n = 1441, Hazard Ratio = 1.75; 95% Confidence Interval = 1.31-2.34; p < 
0.001), suggesting these MCM proteins may cooperate to promote breast cancer progression. Indeed, their expres-
sions were significantly correlated with each other in these cohorts. In addition, we found that increasing number of 
overexpressed MCMs was associated with negative ER status as well as treatment response. Together, our findings 
are reproducible in seven independent breast cancer cohorts, with 1441 patients, and suggest that MCM profiling 
could potentially be used to predict response to treatment and prognosis in breast cancer patients. 
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Introduction 
The minichromosome maintenance (MCM) pro-
tein family ensures that chromosomal replica-
tion occurs only once per cell cycle [1, 2]. MCM 
proteins, including MCM2-7, which are evolu-
tionally conserved in all eukaryotes, form a 
hexameric pre-replication complex that is 
essential for DNA replication initiation and 
elongation [3, 4]. Other than DNA replication, 
MCM proteins have also been shown to play a 
central role in genome stability [5]. 
MCM proteins have been implicated in cancer 
initiation and progression, with their expression 
found to be a determinant of aggressiveness of 
a wide range of epithelial malignancies by 
microarray analysis, suggesting that their up-
regulation is either at a genomic or transcrip-
tional level [6]. As MCM proteins play an impor-
tant role in DNA replication, their role in cancer 
cell proliferation is not surprising [7]. Indeed, 
the expression of MCM proteins has been 
shown to correlate with cell proliferation and 
carcinogenesis [8], and therefore, has been 
suggested to be of diagnostic and prognostic 
value for human malignancy in the clinical set-
ting [9]. For example, only colonocytes from 
patients with symptomatic colorectal cancer 
were positive for MCM2 expression, while those 
from normal healthy patients lacked similar 
expression [10]; MCM2 mRNA overexpression 
has been suggested to be a potential biomark-
er for early diagnosis of colorectal cancer [11]. 
Similarly, MCM2 was demonstrated as a bio-
marker for anal neoplasia [12], esophageal [13, 
14] and bladder cancers [15]. MCM3 overex-
pression was demonstrated in various human 
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cancers [16]. Elevated expression of MCM5 in 
urine sediments has also been shown to be a 
predictive factor for bladder [17] and prostate 
[18] cancers. MCM7 was shown to be a bio-
marker for cervical cancer [19]. Increased 
MCM2 expression is associated with shorter 
survival in prostate cancer [20], lung cancer 
[21], ovarian cancer [22] and renal cell carci-
noma [23, 24] patients, and also with a higher 
risk of recurrence in bladder cancer [25]. 
Increased MCM3 protein also associates with 
poorer survival in brain cancer patients with 
astrocytoma [26]. MCM5 and MCM6 have been 
shown to be an independent prognostic marker 
in patients with ovarian cancer [22] and mela-
noma [27] respectively. Lastly, MCM7 expres-
sion was demonstrated to be a prognostic fac-
tor in colorectal [28], lung [29, 30] and ovarian 
cancers [31].
Despite our understanding of neoplastic regu-
lation by the MCM proteins, little is understood 
regarding the prognostic value of this family of 
proteins. MCM4 was shown to be overex-
pressed in esophageal cancer with higher path-
ological stage [32] and its increased expres-
sion has been associated with shorter survival 
in patients with melanoma [27]. High level of 
MCM4 was demonstrated to be associated 
with cancer initiation but not patient survival in 
lung cancer [33]. Recently, a hypomorphic 
allele of the MCM4 gene in mouse was found to 
increase the risk of breast cancer likely through 
chromosome instability induced by impairment 
in regulation of DNA replication [34]. In breast 
cancer, MCM2 has been shown to be a strong 
prognostic marker, where a high level of MCM2 
expression is shown to associate with survival, 
regional recurrence and distant metastases 
[35]. However, other than MCM2, little is known 
regarding the prognostic value of other MCM 
components in breast cancer. Recently, a via-
ble allele of MCM4 was discovered, suggesting 
MCM4 plays a role in the development of breast 
adenocarcinoma [34]. Despite these results, to 
the best of our knowledge, the expression of 
MCM4 in human specimens and its association 
with human breast cancer progression has not 
been described. In this study, we initially inves-
tigated the prognostic significance of MCM4 in 
our breast cancer patient cohort and other 
cohorts, which are available in online databas-
es. We have discovered a significant role for 
MCM4 overexpression in human breast cancer, 
although the association between MCM4 
expression and disease prognosis was rather 
weak. For this reason, we extended our study to 
involve the major components of the MCM rep-
lication initiation complex, MCM2-7 for better 
prognostication for breast cancer patients.  
Materials and methods
Patients and samples
Breast cancer cases with available frozen tis-
sues for both breast cancer and non-tumor 
breast epithelium were retrieved from Depart- 
ment of Pathology, Queen Mary Hospital, Hong 
Kong. The tissue samples were procured from 
snap-frozen tissues collected immediately after 
surgical resection. Breast cancer with > 75% 
tumor nuclei and the corresponding adjacent 
normal breast epithelium were used for RNA 
extraction and for comparison. In total, 35 pairs 
of breast cancer and adjacent normal breast 
epithelium had enough tissue for RNA extrac-
tion and RT-PCR analysis for MCM4, while 45 
pairs had enough tissue for immunohistochem-
ical staining for MCM4. In addition, another 46 
breast cancer cases with no available adjacent 
normal tissue was used for analysis of the cor-
relation between MCM4 expression and ER sta-
tus by immunohistochemical staining for 
MCM4.
Total RNA extraction and quantitative RT-PCR
Total RNA was extracted using Trizol reagent 
(Invitrogen, Carlsbad, CA) according to the man-
ufacturer’s instructions. Thirty 16 micron thick 
sections of each frozen tissue were used for 
total RNA extraction. Contaminant DNA in the 
RNA samples was digested by DNase I 
(Invitrogen) and the purified RNA was reverse 
transcribed by SuperScript III reverse transcrip-
tase according to manufacturer’s instruction 
(Invitrogen). Real-time PCR was performed 
using SYBR Green Master Mix (Applied 
Biosystems, Warrington, UK) according to the 
manufacturer’s instructions. A four-point cali-
bration standard curve was set by serial dilu-
tion of linearized plasmid for RNA quantifica-
tion. MCM4 was amplified by MCM4 cDNA 
specific primers (5’-CAGCAGCAGAAGATATAG- 
TGGCA-3’ and 5’-CTCCCCAAGTCGTTGCATGT-3’), 
while TATA-binding protein was used as a load-
ing control (Primer sequences; 5’-ACGAACC- 
ACGGCACTGAT-3’ and 5’GCTGGAAAACCCAACT- 
TCTG-3’). The real-time PCR reaction was per-
formed on ABI Prism 7700 (Applied Biosystems). 
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Immunohistochemical staining
Immunohistochemical staining was performed 
using the DakoCytomation EnVision Dual Link 
System-HRP (Dako, Glostrup, Demark) accord-
ing to the manufacturer’s instructions. Briefly, 
the tissue sections were deparaffinized, hydrat-
ed and then placed in a microwave oven at 
95oC in 1 mM EDTA solution (pH 8.0) for 15 min 
for antigen retrieval. The sections were probed 
with 1:200 primary mouse monoclonal anti-
MCM4 antibodies (SC-28317; Santa Cruz 
Biotech, Santa Cruz, CA) at 25°C for one hour. 
Biotin-labeled anti-mouse immunoglobulin was 
used as secondary antibody and the signal was 
developed using chromogen DAB. The stained 
sections were assessed by a pathologist (U.S.K) 
with no prior knowledge of the clinicopathologi-
cal data for the patients. Both cores of each 
specimen were individually scored from 0 to 4, 
which indicated no nuclear staining, 1-25% 
nuclei stained positive, 25-50% nuclei stained 
positive, 50-75% nuclei stained positive and 
75%-100% nuclei stained positive, respec- 
tively. 
Extraction of clinical and microarray gene 
expression data from breast cancer patient 
datasets
Seven breast cancer patient datasets, GS- 
E1456 [36], GSE2034 [37], GSE3143 [38], 
GSE3494 [39], GSE7390 [40], GSE11121 [41] 
and GSE12276 [42], with survival status avail-
able, one breast cancer dataset, GSE5462 
[43], with pre- and post-letrozole treatment 
data available, and three breast cancer patient 
datasets, GSE22093 [44], GSE22358 [45] and 
GSE42822 [46], with treatment response avail-
able, in the Gene Expression Omnibus (GEO) 
Database (http://www.ncbi.nlm.nih.gov/gds) 
were included in this study. The extraction and 
data analysis were performed as previously 
described [47]. 
Statistical analysis
The statistical analysis was performed using 
SPSS 19.0. Differences in expression levels of 
MCM4 mRNA and protein between tumor and 
normal breast tissue in our cohort were ana-
lyzed using paired-t test. The associations 
between expression levels of genes were ana-
lyzed by Spearman’s rank test. Expression lev-
els were further divided into high and low levels 
using median expression level as the cut-off 
point for Kaplan-Meier survival analysis. Re- 
sults were compared by log-rank test. Univariate 
Cox regression was used to correlate the gene 
expression levels and patient survival and mul-
tivariate Cox-regression analysis was used to 
identify independent predictors for patient sur-
vival using a forward stepwise approach with 
an entry limit of p < 0.05.
Figure 1. Differential expression of MCM4 in paired breast cancer and non-tumor breast epithelium specimens. A. 
mRNA expression of MCM4 determined by Real-time PCR in the 35 pairs of tumor and non-tumor specimens. B. 
Protein expression of MCM4 determined by immunohistochemical staining of the 45 pairs of tumor and non-tumor 
specimens.
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Figure 2. The association between MCM4 expression and ER status of breast tumors. (A) Protein expression of MCM4 determined by immunohistochemical staining 
in 90 breast cancer specimens with different ER status. (B-D) Relative expression of MCM4 mRNA determined by microarray analysis in breast cancer specimens 
with different ER status in (B) GSE2034, (C) GSE3494 and (D) GSE7390 breast cancer datasets. (E) Percentage of cases with high or low MCM4 mRNA expression 
in breast cancer specimens with different ER status in the combined breast cancer dataset.
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Figure 3. The association between MCM4 expression and histological grading of breast cancers. (A) Protein expression of MCM4 determined by immunohistochemi-
cal staining in 91 breast cancer specimens with different histological grading. (B-E) Relative expression of MCM4 mRNA determined by microarray analysis in breast 
cancer specimens with different histological grading in (B) GSE1456, (C) GSE3494, (D) GSE7390 and (E) GSE11121 breast cancer datasets.
MCMs in breast cancer prognosis
57 Am J Cancer Res 2015;5(1):52-71
Results
MCM4 mRNA and protein expressions in hu-
man breast cancer specimens
MCM4 mRNA expression was tested by RT-PCR 
in 35 pairs of non-tumor and tumor human 
breast specimens. As shown in Figure 1A, 
human breast cancer specimens expressed a 
significantly higher level of MCM4 mRNA com-
pared to non-tumor human breast epithelium 
specimens (Wilcoxon test; P < 0.001). The 
result was confirmed by IHC staining of MCM4 
proteins in 45 pairs of tumor and non-tumor 
FFPE human breast specimens. Human breast 
cancer specimens had a significantly higher 
level of MCM4 protein expression compared to 
non-tumor specimens (Paired t-test, P < 0.001; 
Figure 1B). These results suggest that 
increased MCM4 mRNA and protein expres-
sions are associated with human breast cancer 
development. 
The association between MCM4 expression 
and ER status in human breast cancer speci-
mens
The association between MCM4 expression 
and ER status was assessed in the FFPE human 
breast cancer specimens for which ER status 
was known (n = 90; 45 pairs specimens); 46% 
of ER-negative breast cancer specimens 
(16/35) stained with a high level of MCM4 pro-
tein, while only 18% of ER-positive breast can-
cer specimens (10/55) had a similar MCM4 
staining extent (Fisher’s Exact test, P = 0.006; 
Figure 2A). To confirm the finding in our breast 
cancer patient cohort, we utilized the Gene 
Expression Omnibus (GEO) database available 
online and identified three independent breast 
cancer datasets comprising information for 
MCM4 mRNA expression level, ER status of the 
tumor and survival status and time. In GSE2034 
(n = 286), GSE3494 (n = 232) and GSE7390 (n 
= 198), MCM4 mRNA expression was signifi-
cantly higher in ER-negative breast cancer com-
pared to ER-positive breast cancer (ANOVA, P ≤ 
0.001; Figure 2B-D). When the three datasets 
were combined and analyzed (n = 716), MCM4 
mRNA was again significantly (Fisher’s Exact 
test, P < 0.001) expressed to a greater degree 
in patients with ER-negative (72%, 123/172) 
tumors than those with ER-positive disease 
(43%, 234/544; Figure 2E). These results indi-
cate that breast cancers, which are indepen-
dent of ER signaling, may have a higher expres-
sion of MCM4. 
The association between MCM4 expression 
and histological grading of human breast can-
cer specimens
In our breast cancer patient cohort, intensity of 
MCM4 staining increased significantly with 
increasing histological grade of tumors; 11% of 
those with grade 1 tumors (1/9) had high stain-
ing for MCM4, while 19% of grade 2 (5/27) and 
39% of grade 3 (21/54) tumors had a high level 
staining of MCM4 (Chi Square test, P < 0.001; 
Figure 3A). Again, we identified four indepen-
dent breast cancer patient datasets that com-
prised information detailing MCM4 mRNA 
expression level, histological grade (histologi-
cal grade was not available in the other 3 breast 
cancer datasets), and survival status and time. 
These datasets were further evaluated for the 
association between MCM4 expression and 
histological grade of breast cancer. In GSE1456 
(n = 147), GSE3494 (n = 234), GSE7390 (n = 
196) and GSE11121 (n = 200), grade 3 breast 
cancer had a significantly higher level of MCM4 
mRNA expression than grade 1 or grade 2 
breast cancer (ANOVA, P < 0.001; Figure 3B-E). 
The association between MCM4 expression 
and survival of human breast cancer patients
We proceeded to investigate whether MCM4 
expression could be a prognostic factor for 
human breast cancer. Seven human breast 
cancer datasets that comprised more than 150 
patients and for whom MCM4 mRNA expres-
sion, and survival status and time was avail-
able, were identified from the GEO database. In 
GSE1456 (n = 159), GSE3494 (n = 236) and 
GSE12276 (n = 204), a significant association 
between high level mRNA expression of MCM4 
and a shorter survival was observed (Wilcoxon-
Gehan test, P = 0.001, = 0.023 and < 0.001, 
respectively; Figure 4A, 4D and 4G). In 
GSE2034 (n = 286), GSE3141 (n = 158) and 
GSE11121 (n = 200), an insignificant trend 
between a high level expression of MCM4 and 
a shorter survival was seen (Wilcoxon-Gehan 
test, P = 0.141, = 0.060 and = 0.247, respec-
tively; Figure 4B, 4C and 4F). In GSE7390, the 
two groups of patients expressing high or low 
level of MCM4 mRNA had similar survival time 
as shown in a Kaplan Meier curve (Wilcoxon-
Gehan test, P = 0.740; Figure 4E). When all the 
seven datasets were combined (n = 1441), a 
high level of MCM4 mRNA expression was 
strongly associated with a shorter survival time 
(Wilcoxon-Gehan test, P < 0.001; Figure 4H). 
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Figure 4. The association between MCM4 
expression and survival of breast cancer pa-
tients. MCM4 mRNA expression was stratified 
into high or low expression using the median 
mRNA expression level as the cut-off point. 
Kaplan-Meier survival curve for MCM expres-
sion and the p-value for log-rank test showed 
alongside for (A) GSE1456, (B) GSE2034, 
(C) GSE3143, (D) GSE3494, (E) GSE7390, 
(F) GSE11121, (G) GSE12276 and (H) for all 
seven breast cancer datasets combined. 
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Table 1. Correlation among the expression levels of MCM family members in seven breast cancer pa-
tient cohorts; (A) GSE1456, (B) GSE2034, (C) GSE3141, (D) GSE3494, (E) GSE7390, (F) GSE11121, 
(G) GSE12276
A. GSE1456 dataset (n = 159) MCMs correlation
MCM2 MCM3 MCM4 MCM5 MCM6 MCM7
Spearman’s rho MCM2 Correlation Coefficient 1.000 .632** .734** .579** .403** .696**
P value . < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
MCM3 Correlation Coefficient .632** 1.000 .621** .588** .381** .682**
P value < 0.001 . < 0.001 < 0.001 < 0.001 < 0.001
MCM4 Correlation Coefficient .734** .621** 1.000 .556** .378** .592**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
MCM5 Correlation Coefficient .579** .588** .556** 1.000 .420** .586**
P value < 0.001 < 0.001 < 0.001 . < 0.001 < 0.001
MCM6 Correlation Coefficient .403** .381** .378** .420** 1.000 .431**
P value < 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
MCM7 Correlation Coefficient .696** .682** .592** .586** .431** 1.000
P value. < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 .
B. GSE2034 dataset (n = 286) MCMs correlation
MCM2 MCM3 MCM4 MCM5 MCM6 MCM7
Spearman’s rho MCM2 Correlation Coefficient 1.000 .622** .569** .615** .707** .653**
P value . < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
MCM3 Correlation Coefficient .622** 1.000 .431** .474** .591** .506**
P value < 0.001 . < 0.001 < 0.001 < 0.001 < 0.001
MCM4 Correlation Coefficient .569** .431** 1.000 .432** .459** .536**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
MCM5 Correlation Coefficient .615** .474** .432** 1.000 .592** .548**
P value < 0.001 < 0.001 < 0.001 . < 0.001 < 0.001
MCM6 Correlation Coefficient .707** .591** .459** .592** 1.000 .459**
P value < 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
MCM7 Correlation Coefficient .653** .506** .536** .548** .459** 1.000
P value. < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 .
C. GSE3141 dataset (n = 158) MCMs correlation
MCM2 MCM3 MCM4 MCM5 MCM6 MCM7
Spearman’s rho MCM2 Correlation Coefficient 1.000 .475** .352** .341** .487** .362**
P value . < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
MCM3 Correlation Coefficient .475** 1.000 .149 .353** .466** .361**
P value < 0.001 . 0.062 < 0.001 < 0.001 < 0.001
MCM4 Correlation Coefficient .352** .149 1.000 .098 .466** .255**
P value < 0.001 0.062 . 0.222 < 0.001  0.001
MCM5 Correlation Coefficient .341** .353** .098 1.000 .317** .477**
P value < 0.001 < 0.001 0.222 . < 0.001 < 0.001
MCM6 Correlation Coefficient .487** .466** .466** .317** 1.000 .344**
P value < 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
MCM7 Correlation Coefficient .362** .361** .255** .477** .344** 1.000
P value. < 0.001 < 0.001 0.001 < 0.001 < 0.001 .
D. GSE3494 dataset (n = 236) MCMs correlation
MCM2 MCM3 MCM4 MCM5 MCM6 MCM7
Spearman’s rho MCM2 Correlation Coefficient 1.000 .688** .654** .690** .530** .659**
P value . < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
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MCM3 Correlation Coefficient .688** 1.000 .515** .614** .493** .634**
P value < 0.001 . < 0.001 < 0.001 < 0.001 < 0.001
MCM4 Correlation Coefficient .654** .515** 1.000 .526** .431** .533**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
MCM5 Correlation Coefficient .690** .614** .526** 1.000 .444** .549**
P value < 0.001 < 0.001 < 0.001 . < 0.001 < 0.001
MCM6 Correlation Coefficient .530** .493** .431** .444** 1.000 .407**
P value < 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
MCM7 Correlation Coefficient .659** .634** .533** .549** .407** 1.000
P value. < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 .
E. GSE7390 dataset (n = 198) MCMs correlation
MCM2 MCM3 MCM4 MCM5 MCM6 MCM7
Spearman’s rho MCM2 Correlation Coefficient 1.000 .616** .578** .636** .664** .669**
P value . < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
MCM3 Correlation Coefficient .616** 1.000 .513** .605** .569** .682**
P value < 0.001 . < 0.001 < 0.001 < 0.001 < 0.001
MCM4 Correlation Coefficient .578** .513** 1.000 .518** .540** .574**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
MCM5 Correlation Coefficient .636** .605** .518** 1.000 .636** .673**
P value < 0.001 < 0.001 < 0.001 . < 0.001 < 0.001
MCM6 Correlation Coefficient .664** .569** .540** .636** 1.000 .646**
P value < 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
MCM7 Correlation Coefficient .669** .682** .574** .673** .646** 1.000
P value. < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 .
F. GSE11121 dataset (n = 200) MCMs correlation
MCM2 MCM3 MCM4 MCM5 MCM6 MCM7
Spearman’s rho MCM2 Correlation Coefficient 1.000 .710** .689** .624** .778** .629**
P value . < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
MCM3 Correlation Coefficient .710** 1.000 .571** .432** .666** .594**
P value < 0.001 . < 0.001 < 0.001 < 0.001 < 0.001
MCM4 Correlation Coefficient .689** .571** 1.000 .508** .645** .539**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
MCM5 Correlation Coefficient .624** .432** .508** 1.000 .650** .553**
P value < 0.001 < 0.001 < 0.001 . < 0.001 < 0.001
MCM6 Correlation Coefficient .778** .666** .645** .650** 1.000 .558**
P value < 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
MCM7 Correlation Coefficient .629** .594** .539** .553** .558** 1.000
P value. < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 .
G. GSE12276 dataset (n = 204) MCMs correlation
MCM2 MCM3 MCM4 MCM5 MCM6 MCM7
Spearman’s rho MCM2 Correlation Coefficient 1.000 .673** .554** .618** .698** .665**
P value . < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
MCM3 Correlation Coefficient .673** 1.000 .605** .631** .688** .656**
P value < 0.001 . < 0.001 < 0.001 < 0.001 < 0.001
MCM4 Correlation Coefficient .554** .605** 1.000 .500** .535** .637**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
MCM5 Correlation Coefficient .618** .631** .500** 1.000 .724** .631**
P value < 0.001 < 0.001 < 0.001 . < 0.001 < 0.001
MCM6 Correlation Coefficient .698** .688** .535** .724** 1.000 .660**
P value < 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
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These results suggest that MCM4 mRNA 
expression, by itself, may be a weak prognostic 
marker for human breast cancer progression.
mRNA expression levels of MCMs are highly 
correlated with each other
MCM family members MCM2-7 work as a com-
plex to regulate DNA replication, so it is perhaps 
unsurprising that overexpression of MCM4 
alone may not be highly significantly associated 
with poor prognosis of breast cancer patients. 
Indeed, it is possible that overexpression of 
other components of the MCM complex may 
also be important for breast cancer progres-
sion. To investigate this, the correlations 
between the expression levels of MCMs were 
tested in the seven breast cancer datasets pre-
viously used for MCM4/disease progression 
correlation analysis. As shown in Table 1, the 
mRNA expression levels of all the MCMs were 
statistically significantly correlated with each 
other in all seven datasets (Spearman’s rank 
test, P < 0.05), except between MCM3 and 
MCM4, and between MCM4 and MCM5 in 
GSE3141. These results suggest that MCM2-7 
may be transcriptionally regulated together in 
breast cancer. Indeed, DNA sequence analysis 
of the 2000 base pairs upstream of the tran-
scriptional start sites for MCM2-7 using 
TFSEARCH, at a score cutoff of 90, identified 
three potential transcription factors that may 
bind to promoters of all six MCMs. As shown in 
Table 2, several transcription factors were 
identified that may bind and regulate the tran-
scription of more than one MCM gene. 
Specifically, the transcription factors, AML-1a, 
GATA-1 and SRY were identified as having the 
potential to bind to upstream sequences of all 
MCM2-7 genes (Table 2, highlighted). Together, 
these results suggest that MCM2-7 genes may 
be closely co-regulated in breast cancer by 
common transcription factors. 
The prognostic significance of other MCMs in 
human breast cancer
As the expression of MCM components in the 
MCM replication complex was shown to be pos-
itively correlated, and as each component may 
contribute to the function of the complex in 
regulating DNA replication, the prognostic sig-
MCM7 Correlation Coefficient .665** .656** .637** .631** .660** 1.000
P value. < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 .
**Correlation is significant at the 0.01 level (2-tailed).
Table 2. Summary of TFSEARCH results 
indicating transcription factors that may 
potentially bind and regulate the MCM family 
members. Highlighted are the transcription 
factors predicted to bind upstream of all six 
MCM members
Potential transcription factors regulating expres-
sion of MCMs
AML-1a MCM2-7
AP-1 MCM2, 4, 5 and 7
CDP CR MCM3, 7
CdxA MCM2-7
C/EBP MCM3 and 4
C/EBPb MCM2, 3 and 5
c-Ets MCM2, 3 and 7
CP2 MCM4, 7
c-Rel MCM2, 4 and 6
CREB MCM2, 5
Delta-E MCM4-7
E2F MCM3, 5 and 6
E47 MCM6
Elk-1 MCM7
Evi-1 MCM2
GATA-1 MCM2-7
GATA-2 MCM2-6
GATA-3 MCM2,4 and 6
GATA-x MCM2 and 3
HFH-1 MCM5 and 7
HFH-2 MCM3, 5 and 7
HFH-3b MCM3, 5-7
HSF1 MCM3 and 5
HSF2 MCM2, 3 and 5
Ik-2 MCM2 and 5
Lyf-1 MCM2, 4-7
MZF1 MCM2-5 and 7
NF-E2 MCM7
NF-kap MCM2, 4 and 6
Nkx-2 MCM2-5 and 7
NRF-2 MCM7
Oct-1 MCM3 and 4
P300 MCM7
Pbx-1 MCM3, 6 and 7
S8 MCM5-7
Sox-5 MCM2-4 and 7
SP1 MCM3 and 4
SREBP MCM2 and 4-7
SRY MCM2-7
STATx MCM6
v-Myb MCM3
YY1 MCM6
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Figure 5. The association between MCMs 
expression and survival of breast can-
cer patients. MCM mRNA expression was 
stratified into high or low expression using 
the median mRNA expression level as the 
cut-off point. Kaplan-Meier survival curve 
for (A) MCM2, (B) MCM3, (C) MCM5, (D) 
MCM6 and (E) MCM7 expression and the 
p-value for log-rank test showed alongside 
for the combined breast cancer dataset.
nificance of the other components, MCM2, 
MCM3, MCM5, MCM6 and MCM7, was asse- 
ssed in the combined breast cancer dataset (n 
= 1441). As was the case with MCM4, when 
high mRNA expression was significantly associ-
ated with shorter breast cancer patient survival 
(Wilcoxon-Gehan test, χ2 = 14.648, P < 0.001; 
Figure 4H), so was high mRNA expression of 
MCM2 (Wilcoxon-Gehan test, χ2 = 32.988, P < 
0.001; Figure 5A), MCM3 (Wilcoxon-Gehan 
test, χ2 = 12.184, P < 0.001; Figure 5B), MCM5 
(Wilcoxon-Gehan test, χ2 = 11.861, P = 0.001; 
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Table 3. Correlation between the number of MCMs 
overexpressed and the prognosis for patients in 
seven breast cancer cohorts; (A) GSE1456, (B) 
GSE2034, (C) GSE3141, (D) GSE3494, (E) GSE7390, 
(F) GSE11121, (G) GSE12276
A. Cox-regression analysis for GSE1456 (n = 159)
Factor Hazard Ratio 95% CI P value
MCMs overexpression
    0 MCM Reference
    1 MCMs 1.03 0.21-5.09 0.974
    2 MCMs 1.20 0.24-5.95 0.823
    3 MCMs 1.99 0.40-9.88 0.399
    4 MCMs 2.75 0.66-11.53 0.166
    5 MCMs 1.72 1.43-18.00 0.012
    6 MCMs 1.75 1.19-15.37 0.026
B. Cox-regression analysis for GSE2034 (n = 286)
Factor Hazard Ratio 95% CI P value
MCMs overexpression
    0 MCM Reference
    1 MCMs 2.11 1.00-4.43 0.049
    2 MCMs 1.54 0.71-3.35 0.278
    3 MCMs 1.78 0.78-3.97 0.160
    4 MCMs 1.81 0.81-4.03 0.149
    5 MCMs 1.85 0.86-3.98 0.117
    6 MCMs 2.11 1.01-4.41 0.046
C. Cox-regression analysis for GSE3141 (n = 158)
Factor Hazard Ratio 95% CI P value
MCMs overexpression
    0 MCM Reference
    1 MCMs 2.24 0.69-7.31 0.182
    2 MCMs 1.12 0.28-4.52 0.873
    3 MCMs 1.52 0.41-5.68 0.537
    4 MCMs 2.49 0.80-7.75 0.115
    5 MCMs 2.17 0.65-7.25 0.207
    6 MCMs 5.02 1.48-17.05 0.010
D. Cox-regression analysis for GSE3494 (n = 236)
Factor Hazard Ratio 95% CI P value
MCMs overexpression
    0 MCM Reference
    1 MCMs 1.39 0.45-4.24 0.565
    2 MCMs 1.14 0.33-3.94 0.837
    3 MCMs 2.35 0.79-7.02 0.126
    4 MCMs 1.86 0.54-6.44 0.327
    5 MCMs 2.07 0.71-6.05 0.185
    6 MCMs 2.78 0.99-7.80 0.052
E. Cox-regression analysis for GSE7390 (n = 198)
Factor Hazard Ratio 95% CI P value
MCMs overexpression
    0 MCM Reference
    1 MCMs 1.74 0.53-5.72 0.360
Figure 5C), MCM6 (Wilcoxon-Gehan test, χ2 
= 24.442, P < 0.001; Figure 5D) and MCM7 
(Wilcoxon-Gehan test, χ2 = 14.401, P < 
0.001; Figure 5E). These results suggest 
that overexpression of MCM components 
is associated with breast cancer progre- 
ssion. 
Combined MCMs overexpression score as 
a prognostic indicator for breast cancer
As overexpression of any of the compo-
nents in the MCM replication complex was 
associated with poorer survival of breast 
cancer patients, we hypothesized that a 
combinatorial analysis of expression levels 
of MCMs could be a better prognostic 
marker for breast cancer. As shown in 
Table 3A, patients from dataset GSE1456, 
whose tumors overexpressed five or six 
MCMs had a significantly higher risk of 
death compared to those whose tumors 
did not overexpress any of the MCMs (Cox-
regression analysis - Table 3A). In addition, 
Kaplan-Meier analysis showed that pati- 
ents whose breast tumors overexpressed 
four or more MCM components had a sig-
nificantly shorter survival time compared to 
those whose tumors overexpressed three 
or fewer MCMs (Wilcoxon-Gehan test, P < 
0.001; Figure 6A). Similar results were 
obtained in the other six independent 
breast cancer patient cohorts included in 
our study. By Cox-regression analysis, pati- 
ents whose tumors overexpressed six 
MCMs had a significantly higher risk of 
death compared to those patients whose 
tumors did not overexpress any of the 
MCMs in GSE2034 (Table 3B), GSE3141 
(Table 3C), GSE3494 (Table 3D), GS- 
E11121 (Table 3F) and GSE12276 (Figure 
3G) breast cancer cohorts, while patients 
whose tumors overexpressed four or five 
MCMs, or three, four or five MCMs also had 
a significantly higher risk of death com-
pared to those patients whose tumors did 
not overexpress any of the MCMs in 
GSE7390 (Table 3E) and GSE12276 (Table 
3G), respectively. By Kaplan-Meier analy-
sis, patients whose tumors overexpressed 
4 or more MCMs had a significantly shorter 
survival time than those patients whose 
tumors overexpressed three or fewer 
MCMs in GSE3141, GSE3494, GSE7390, 
GSE11121 and GSE12276 (P < 0.05; 
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    2 MCMs 1.98 0.57-6.86 0.281
    3 MCMs 1.93 0.52-7.19 0.329
    4 MCMs 8.81 3.26-23.78 < 0.001
    5 MCMs 4.39 1.52-12.67 0.006
    6 MCMs 1.43 0.45-4.52 0.539
F. Cox-regression analysis for GSE11121
Factor Hazard Ratio 95% CI P value
MCMs overexpression
    0 MCM Reference
    1 MCMs 1.25 0.77-2.03 0.364
    2 MCMs 1.29 0.76-2.20 0.346
    3 MCMs 2.07 1.21-3.54 0.008
    4 MCMs 2.65 1.57-4.46 < 0.001
    5 MCMs 1.82 1.12-2.95 0.015
    6 MCMs 2.18 1.42-3.33 < 0.001
G. Cox-regression analysis for GSE12276
Factor Hazard Ratio 95% CI P value
MCMs overexpression
    0 MCM Reference
    1 MCMs 2.78 0.72-10.75 0.139
    2 MCMs 3.63 0.91-14.52 0.069
    3 MCMs 3.43 0.86-13.74 0.081
    4 MCMs 3.41 0.85-13.65 0.083
    5 MCMs 3.16 0.71-14.13 0.132
    6 MCMs 4.16 1.20-14.49 0.025
Figure 6C-G), while a similar trend, although not 
statistically significant, was observed in 
GSE2034 (Figure 6B). In the combined breast 
cancer dataset consisting of 1441 breast can-
cer patients, overexpression of increasing num-
ber of MCMs is a strong prognostic indictor 
(Wilcoxon-Gehan test, χ2 = 39.787, P < 0.001; 
Figure 6H), while patients whose tumors over-
expressed 4 or more MCMs had a significantly 
shorter survival time compared to those 
patients whose tumors overexpressed three or 
fewer MCMs by Kaplan-Meier analysis (Wil- 
coxon-Gehan test, χ2 = 35.189, P < 0.001; 
Figure 6I). These results strongly suggest that 
the combinatorial use of the expression levels 
of MCM2-7 is a reliable prognostic indicator for 
breast cancer patients. As shown by the 
Wilcoxon-Gehan test in Figures 4H, 5A-E, and 
6H-I, the combinatorial use of the expression 
levels of MCMs resulted in the highest χ2 values 
compared to individual use of any of them. 
Indeed, by using univariate Cox-regression 
analysis, we found that overexpression of three 
MCMs is barely significantly associated with an 
increased hazard ratio, while overexpression of 
used as predictive indicator for response to 
anti-cancer therapy. 
The association between MCM expression and 
breast cancer patient survival is dependent on 
the ER status
As MCM4 expression was associated with ER 
status of breast tumors (Figure 2), we investi-
gated whether the association between MCM4 
and survival was dependent on the ER status 
breast tumor. In the three GEO database breast 
cancer patient cohorts (GSE2034, GSE3494 
and GSE7390) that detailed ER status totaling 
716 patients, the association between MCM4 
and survival was only observed in patients 
whose breast tumors were ER positive (P = 
0.013; Figure 8B), and not in those patients 
whose tumors were ER negative (P = 0.487; 
Figure 8A). Interestingly, ER positive breast 
cancer was associated with significantly higher 
expression of all the individual MCMs (MCM2-
7) in all three independent breast cancer data-
sets (ANOVA, P < 0.05; data not shown). As 
shown in Figure 8C, significantly more ER nega-
tive breast tumors overexpressed more MCM 
four, five or six MCMs were all statistically 
significantly associated with an increased 
hazard ratio (Table 4A). The addition of 
any of the individual MCMs by multivariate 
Cox-regression analysis was not statisti-
cally significant (Table 4B), suggesting that 
additional information of the expression of 
any of the individual MCMs does not con-
tribute significantly to the prognosis of 
breast cancer on top of the MCMs combi-
natorial expression score. 
The association between MCMs expres-
sion and the response to treatment
As MCMs expression was associated with 
prognosis of breast cancer patients, we 
further investigated whether expression of 
MCMs is associated with response to vari-
ous anti-cancer treatments, including che-
motherapies or trastuzumab, in three dif-
ferent breast cancer patient datasets 
(GSE22093, GSE22358 and GSE42822). 
We found that breast tumors that respond-
ed better (determined by pathological com- 
plete response; pCR) to treatment overex-
pressed statistical significantly more MC- 
Ms than those tumors overexpressing 
fewer MCMs (Figure 7). These results sug-
gest that expression of MCMs can also be 
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components compared to ER positive breast 
tumors (Chi-Square test, P < 0.001). While only 
33% of the ER positive breast tumors had 4 or 
more MCMs overexpressed, 76% of the ER neg-
ative breast tumors had the same extent of 
MCMs overexpression (Fisher’s Exact test, P < 
0.001; Figure 8D). Interestingly, the number of 
MCMs overexpressed was significantly associ-
ated with patient survival time only in patients 
with ER positive breast tumors (Wilcoxon-
Gehan test, P = 0.006; Figure 8F) but not in 
those patients with ER negative tumors 
(Wilcoxon-Gehan test, P = 0.281; Figure 8E). 
The impact of ER-targeting hormonal therapy 
on MCM expression was assessed in a breast 
cancer dataset where the patients were treat-
ed with letrozole, and for whom pre-treatment 
cancer patients. However, the prognostic sig-
nificance of MCM4 alone is rather weak; 
although a high level of MCM4 expression is 
statistically significantly associated with breast 
cancer patient survival, the significant associa-
tion is not robustly observed in the seven inde-
pendent breast cancer patient cohorts, each 
with more than 150 patients, included in the 
current study. Expression levels of all the MCM 
components in the MCM replication complex 
are highly correlated with each other, indicating 
that they may be regulated by similar transcrip-
tion factors or signaling pathways. Expression 
level of each MCM in the MCM replication com-
plex, itself, is associated with breast cancer 
patient survival, suggesting that these MCMs, 
individually, could contribute to breast cancer 
prognosis, and co-overexpression of these 
Figure 6. The association between a combinatorial score for MCM2-7 expression and survival of breast cancer 
patients. (A-G) MCM mRNA expression was stratified into high or low expression using the median mRNA expres-
sion level as the cut-off point. Specimens were than stratified into two groups by the number of MCMs expressed 
at a high level (≤ 3 MCMs or ≥ 4 MCMs expressed at a high level). Kaplan-Meier survival curve for a combinatorial 
score for MCM2-7 expression and the p-value for log-rank test showed alongside for (A) GSE1456, (B) GSE2034, 
(C) GSE3141, (D) GSE3494, (E) GSE7390, (F) GSE11121 and (G) GSE12276. (H) Kaplan-Meier survival curve for 
specimens stratified into seven groups based on the number of MCMs expressed at a high level. (I) Kaplan-Meier 
survival curve for specimens stratified into two groups based on the number of MCMs expressed at a high level (≤ 
3 MCMs or ≥ 4 MCMs expressed at a high level).
Table 4. Cox-regression analysis reveals that overex-
pression of four or more MCMs poses a significantly 
higher hazard ratio than that posed in patients overex-
pressing three or fewer MCMs
A. Cox-regression analysis
Factor Hazard Ratio 95% CI P value
MCMs overexpression
    0 MCM Reference
    1 MCMs 1.22 0.89-1.67 0.216
    2 MCMs 1.09 0.77-1.54 0.610
    3 MCMs 1.35 0.96-1.90 0.082
    4 MCMs 1.84 1.35-2.52 < 0.001
    5 MCMs 1.72 1.26-2.34 0.001
    6 MCMs 1.75 1.31-2.34 < 0.001
B. P value for inclusion in the multivariate Cox-regression 
analysis
Factor P-value for inclusion
    MCM2 0.061
    MCM3 0.198
    MCM4 0.881
    MCM5 0.398
    MCM6 0.308
    MCM7 0.641
and post-treatment specimens were avail-
able [43]. Comparing specimens from pre-
letrozole treatment and post-letrozole 
treatment, we found that mRNA expres-
sion of all six MCMs were lower after treat-
ment with letrozole and that the reduction 
in expression was statistically significant 
in five of the six MCMs (Paired t test; 
MCM2, p < 0.001; MCM3, p = 0.003, 
MCM4, p < 0.001; MCM5, p = 0.083; 
MCM6, p < 0.001; MCM7, p < 0.001). 
Indeed, pre-letrozole treated tumors had 
significantly more MCMs overexpressed 
compared to those after treatment with 
letrozole (Figure 8G), indicating that inhibi-
tion of ER signaling in ER-positive tumors 
leads to reduced expression of MCMs. 
This result suggests that ER signaling is 
important for expression of MCMs. 
Discussion
In this study, we have demonstrated that a 
high level of expression of MCM4 was 
associated with breast cancer progres-
sion, with ER negative or high grade breast 
tumors, as well as survival status of breast 
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Figure 7. The association between MCMs expression 
and the response to treatment. Breast cancer pa-
tients were stratified according to their response to 
therapeutic intervention (namely residual disease or 
pCR for GSE22093 (A); no response, partial response, 
near complete response or complete response for 
GSE22358 (B); no pCR or pCR for GSE42822 (C), and 
this response was correlated with the number of MCM 
genes overexpressed in individuals’ tumors. 
MCMs may be a better prognostic indicator 
than MCM4 or other MCMs alone, which could 
be robustly used for breast cancer prognostica-
tion. Indeed, by both Cox-regression and Ka- 
plan-Meier analyses, the association between 
more MCMs overexpression and a shorter sur-
vival time is observed routinely in all the seven 
independent as well as the combined breast 
cancer patient cohorts totaling 1441 patients. 
Most importantly, by multivariate Cox-regre- 
ssion, inclusion of any of the MCMs in the MCM 
replication complex could not significantly con-
tribute to the power of the combinatorial use of 
MCMs in breast cancer prognosis. 
Although MCM expression is associated with 
ER negative breast tumors, the MCM-survival 
association can only be observed in patients 
with ER positive breast tumors but not in those 
with ER negative tumors. We hypothesize here 
that the loss of ER and the resulting ER signal-
ing-independent  breast cancer may be associ-
ated with uncontrolled MCMs expression. In ER 
positive breast tumors, it is more likely that sig-
naling pathways or transcription factors down-
stream of ER signaling activate mRNA expres-
sion of MCMs, which leads to increased 
proliferation and poorer prognosis of breast 
cancer patients. This hypothesis is supported 
by the result obtained in GSE5462, where letro-
zole treatment resulted in a significant decrease 
in the number of MCMs overexpressed. Our 
results suggest that ER positive breast cancers 
are more dependent on MCMs expression, and 
MCMs may be therapeutic targets for ER posi-
tive breast cancer. 
A previous study has shown a prognostic role 
for MCM2 in breast cancer progression [35], 
the prognostic values of MCM2-7, when consid-
ered alone, is not suitably robust in the seven 
independent breast cancer patient cohorts 
included in the present study. For this reason, a 
better prognostic indictor from MCMs expres-
sion was sought. Here, we show that the asso-
ciation between a combination of MCMs 
expressions and survival could be robustly 
detected in all the seven independent breast 
cancer patient cohorts, together consisting of 
1441 patients, by either Cox-regression analy-
sis or Kaplan-Meier survival analysis. Our 
results suggest that this combinatorial use of 
MCM expression levels could be of clinical sig-
nificance for prognosis of breast cancer 
patients. In addition, the present study has also 
demonstrated that expression of MCMs can 
also be used as predictive indicator for anti-
cancer therapy in three independent breast 
cancer patient datasets, suggesting that com-
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Figure 8. The association of ER status and MCMs 
mRNA expression, survival and response to letro-
zole treatment in breast cancer patients. Kaplan-
Meier survival curve for MCM4 in specimens with 
(A) ER-negative and (B) ER positive status. (C) His-
togram showing the percentage of cases expressing 
different numbers of MCMs at a high level. (D) Histo-
gram showing the percentage of cases expressing ≤ 
3 MCMs or ≥ 4 MCMs at a high level. Kaplan-Meier 
survival curve for MCMs combinatorial score (≤ 3 
MCMs or ≥ 4 MCMs expressed at a high level) in 
specimens with (E) ER-negative and (F) ER positive 
status. (G) Histogram summarizing the impact of le-
trozole treatment on the expression of MCM mRNAs.
binatorial score of MCMs could be of great clini-
cal interests in the future.
There are limitations in our study. Since the 
datasets are downloaded from GEO database, 
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patients in these datasets may be of heteroge-
neous baseline characteristics, treatments, 
while the laboratory experimental procedures 
could be heterogeneous too. Nonetheless, the 
association between high level expression of 
all MCM proteins and shorter survival was con-
sistently observed in all the individual datasets 
analyzed and the combined dataset, suggest-
ing that our findings warrant an independent 
prospective study to confirm the clinical appli-
cability of combining MCM proteins as a prog-
nostic indicator. 
In conclusion, the present study has demon-
strated the importance of MCM2-7 expression 
in breast cancer and showed that the combina-
torial use of the expressions of MCM2-7 could 
be a potential novel prognostic and predictive 
indicator for breast cancer patients. 
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